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Abstract
Background: The factors related to the treatment of nausea during pregnancy have not yet been investigated in
several countries simultaneously. The present study aimed to describe differences in self-reported nausea during
pregnancy and the patterns of use for both conventional and herbal medicines across countries. The factors related
to nausea and its treatment and the relationships between different self-reported co-morbidities and nausea were
also investigated.
Methods: This cross-sectional study used data collected by a web-based questionnaire distributed between October
2011 and February 2012 in several countries within five regions: Western, Northern, and Eastern Europe, North America,
and Australia. Women who were pregnant or had a child less than one year old were eligible to participate.
Results: A total of 9113 women were included in the study, whereof 6701 (73.5 %) had experienced nausea during
pregnancy. Among respondents with nausea, conventional medicines were used by 1201 (17.9 %) women and herbal
medicines by 556 (8.3 %) women. The extent of self-reported nausea and its treatment varied by country. Education,
working status, and folic acid use were significantly associated with the use of conventional medicines against nausea.
Respondents who had nausea also had a high burden of co-morbidity.
Conclusion: The prevalence of nausea was high across all participating countries but its treatment varied, possibly due
to cultural differences and differences in attitudes towards medicines. A high degree of co-morbidity was found among
respondents with nausea.
Keywords: Nausea, Pregnancy, Pharmacotherapy, Herbal medicine, Multinational, Internet
Background
Nausea and vomiting during pregnancy (NVP) is one of
the most common pregnancy-related complaints, affecting
millions of pregnant women worldwide each year. Ap-
proximately 7 out of 10 women experience nausea during
pregnancy [1] and 50 % experience both nausea and
vomiting [2–4]. For most patients, symptoms appear
around the sixth week of pregnancy and gradually decline
during the second trimester, peaking at 8–13 weeks [2, 3].
However, 10 % of women will still experience symptoms
after 20–22 weeks of pregnancy [3, 4]. The most severe
form of NVP, hyperemesis gravidarum, is characterised by
severe and persistent nausea and vomiting leading to
weight loss, ketonuria, nutritional deficiencies, dehydra-
tion and electrolyte imbalance, often so severe as merits
hospitalisation, and affects about 1.1% of the pregnant
women [1].
NVP has been shown to greatly impact a woman’s life,
negatively affecting daily activities, relationship with
partner, parenting, occupation and social functioning
[5–7]. Feelings of isolation, fatigue, depression, and help-
lessness due to nausea have also been described [7–9].
Nausea has been reported to be responsible for 33 % of all
sick leave during pregnancy [10]. In the USA and Canada,
NVP is a significant economic burden to women and
society [11, 12].
Because NVP is often most intense during the first
trimester when organogenesis occurs, teratogenic effects
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are a concern in treatment. This may lead to caution in
prescribing and taking conventional medicines to treat
this condition, despite the proven safety of use during
pregnancy of many medicines. Pregnant women often
overestimate the teratogenic risk associated with the use
of medicines in general [13]. Consequently, many women
may turn to complementary and alternative medicine
(CAM) to alleviate their symptoms or choose to not treat
their symptoms due to the fear that taking anything dur-
ing pregnancy may harm the baby. Despite the high preva-
lence of NVP, little is known about differences in NVP
treatments, i.e. conventional and herbal medicines, across
countries. An informal survey in various European
countries in 1998 found wide variations in the types of
treatment used against mild and moderate nausea and
vomiting, whereas hyperemesis gravidarum was treated in
a similar fashion in the vast majority of countries [14].
No study has investigated the factors related to NVP
treatment in several countries simultaneously. Studies
are available from various countries, but data collection
methods vary [5, 7, 15–20], making direct comparisons
impossible. In addition different therapies have been in-
cluded in the definition of CAM [15, 16, 18, 19].
New possibilities for uniform data collection in several
countries are emerging that are advantageous for the field
of e-epidemiology [21, 22]. Large potential gains in well-
being for the mother and society as a whole can be
achieved with better knowledge on how nausea in preg-
nancy is being treated. This study is the first to investigate
the factors related to the treatment of nausea during
pregnancy at a multinational level.
The present study aimed to describe differences in
self-reported nausea during pregnancy, as well as the
patterns of use of both conventional and herbal medi-
cine across countries in Western, Northern, and Eastern
Europe, North America, and Australia. The study also
aimed to investigate the factors related to nausea and its
treatment, as well as the relationships between different
self-reported co-morbidities and nausea.
Methods
This cross-sectional study was based on data from a web-
based questionnaire covering nausea, medicines against
nausea, herbal medicines against nausea, sociodemographic
factors, maternal health, and lifestyle during pregnancy
[23]. The online questionnaire was distributed simultan-
eously in 18 countries: Austria, Australia, Croatia, Canada,
France, Finland, Iceland, Italy, Norway, Poland, Russia,
Serbia, Slovenia, Sweden, Switzerland, the Netherlands,
United Kingdom, and USA. The original data file consisted
of 9459 women, including 346 South American women
who accessed the questionnaire via North American web-
sites [23]. For this sub-study, the 346 women from South
America were excluded in effort to reduce selection bias as
this was considered a special group of women, resulting in
a final study population of 9113 women.
Women who were pregnant or had a child who was less
than one year old were eligible to participate in the study.
An advert containing a link to the online self-completed
questionnaire was posted on commonly visited pregnancy
and baby related websites in the participating countries.
National coordinators selected the most relevant na-
tional websites, social networks, and pregnancy forums
[23]. The questionnaire was available for 2 months in
each participating country between 1st of October 2011
and 29th of February 2012.
The questionnaire was originally developed in Norwe-
gian and English before being translated into the relevant
languages, and is available online as an appendix to the
paper by Lupattelli et al. [23]. A pilot study was performed
during September 2011 in Norway, Finland, Italy, and
Sweden (n = 47) but resulted in no major changes to the
questionnaire. All national coordinators assured the qual-
ity of their version of the questionnaire.
The representativeness of the study population was
assessed by comparing the sociodemographic and lifestyle
characteristics (i.e., age, marital status, education, and
smoking) of the study population to the general birthing
population in the corresponding country. The similarities
were satisfactory with the exception that the study partici-
pants were generally more educated than the general
birthing population, as described in detail elsewhere [23].
Measures of nausea, health disorders, and conventional
and herbal medicines use during pregnancy
The respondents were presented with a list of questions
related to different health disorders/short-term illnesses
during pregnancy, including nausea, and asked if they had
any of these illnesses. In case of an affirmative response,
the respondents were asked about medicine use related to
each individual illness. The medicines used were reported
in free-text entry fields. The timing of use for both con-
ventional and herbal medicines could also be reported and
were defined by the three possible exposure windows in-
cluded in the questionnaire: weeks 1–12 (first trimester);
weeks 13–24 (second trimester), and week 25 to delivery
(third trimester). A list of chronic disorders was also pre-
sented to the respondents, including cardiovascular and
rheumatic disorders, diabetes and epilepsy, and an open-
ended option. Furthermore, the women were presented
with a question on sick leave during pregnancy (dichoto-
mised yes/no).
In addition to the standardised questions about medi-
cine use for specific illnesses, the respondents were
questioned about over-the-counter (OTC) medicine use
during pregnancy, including OTC medicines against
nausea, and the timing of use. A medicine was defined
Heitmann et al. BMC Pregnancy and Childbirth  (2015) 15:321 Page 2 of 13
as a single product containing one or more active in-
gredients. The main active ingredient(s) and formula-
tion of the branded medicinal product were identified
for each specific trademark name and recorded using
either the national medicine database or the Martindale
textbook [24]. All medicines were then coded into the
corresponding Anatomical Therapeutic Chemical (ATC)
codes in accordance with the World Health Organization
(WHO) ATC index [25]. Whenever possible, the 5th level
of the ATC was used.
Any use of herbal medicines was specifically requested,
including the name of the product, reason for its use,
and the timing of use during pregnancy. The name of
the herbal medicine and the reason for its use were re-
ported as free-text entry fields. Herbal medicine could
also be reported under the disease-specific questions
and the questions about OTC medicine. Herbal medi-
cines were identified by name and coded in accordance
with a pre-determined list of herbs [26].
The respondents were classified as having nausea dur-
ing pregnancy if they reported having had nausea when
questioned about short-term illnesses, if they reported
any use of OTC medicines against nausea, or if they gave
nausea as an indication for the use of herbal or homeo-
pathic medicines.
Sociodemographic and lifestyle variables
The following variables were explored in relation to nau-
sea and the use of conventional medicines: region of
residence, maternal age, parity, marital status, education,
working status, smoking during pregnancy, use of folic
acid, and multiple pregnancy. Sociodemographic vari-
ables were categorised as presented in Table 1.
Measurements of maternal mental health
Symptoms of depression were measured by the Edinburgh
Postnatal Depression Scale (EPDS), a self-rating 10-
item scale initially developed by Cox et al. to detect
postnatal depression [27]. However, the scale has also
been validated as a screening tool for major depression
in pregnant women with satisfactory results and has
been used in several studies in various countries [28].
Cut-off scores of 11, 10 and 10 applied at weeks 12, 24,
and 36 of pregnancy, respectively, resulted in 79 %, 70
%, and 76 % sensitivity, respectively, and 97 %, 96 %,
and 94 % specificity, respectively [28]. Each question
has four different options scored as 0, 1, 2, or 3. The scale
rates the intensity of depressive symptoms over the previ-
ous 7 days. The total score ranges between 0 and 30. Hav-
ing symptoms of depression was defined as having a total
EPDS score ≥13 [27]. Validated translated versions of the
original EPDS were available for eight languages other than
English: Dutch, French, German, Icelandic, Norwegian,
Slovenian, Spanish, and Swedish [29]. The Serbian version
was developed by two independent linguistic experts, who
carried out translations and back-translations. Any discrep-
ancies between the back-translated and original EPDS were
identified and corrected. For the remaining five languages,
the translated versions used in previous studies were uti-
lised [30–33].
Statistical analysis
Descriptive statistics were used to calculate the preva-
lence of conventional and herbal medicines use against
nausea during pregnancy and presented as percentages.
Univariate and multivariate generalised estimating equa-
tion (GEE) analyses were performed to explore potential
significant associations between the maternal character-
istics listed in Table 1 and the use of conventional medi-
cines against nausea. The GEE with the binary logistic
model was used to correct for clustering on region of
residency. Odds ratios (ORs) are presented with 95 %
confidence intervals (CIs). All variables in Table 1, with
the exception of multiple pregnancy, were included in
the multivariate models.
Univariate and multivariate GEE analyses were also used
to explore the relationships between co-morbidity and
nausea and its treatment. First, univariate analyses were
performed. Then full multivariate models were built in-
cluding all variables presented in Table 1. Reduced models
were fit by excluding non-significant variables (signifi-
cance level: p < 0.05), unless removal of the variable
caused a >10 % change in the effect estimates. Sub ana-
lyses including the EPDS were restricted to pregnant
women only, as the EPDS is based on symptoms during
the prior week. Moreover, stratified analyses on timing of
gestation (during first trimester versus after first trimester)
were performed when studying the association between
nausea and comorbidity.
All statistical analyses were performed using Statistical
Package for the Social Sciences (SPSS) version 20.0 (IBM
SPSS Statistics 20) for Windows (SPSS, Chicago, IL, USA).
Ethics
Before entering the online questionnaire, the respondents
had to 1) read the study description in which the study
objectives, the participants’ right to withdraw at any time,
and contact persons in the applicable country were pre-
sented, and 2) answer the following question: “Are you
willing to participate in the study?” If the woman ticked
“yes” as the answer it was considered informed consent.
The study was approved by the Regional Ethics Com-
mittee, Region South-East in Norway, and the relevant
Ethics Boards in each specific country when required
[23]. Complementary ethical approval was required and
obtained from the Faculty of Medicine and Health Sci-
ence Research Ethics Committee of the University of
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Table 1 Factors related to nausea and treatment of nausea
Total
population
Total Nausea Crude OR
(95 % CI)
Adjusted OR
(95 % CI)b
Nausea,
conventional
medicines against
nausea
Crude OR
(95 % CI)
Adjusted OR
(95 % CI)b
Nausea,
conventional
medicines
against
nausea vs.
Nausea, no
treatmentc
Nausea, conventional
medicines against
nausea vs. Nausea,
no treatmentc
n = 9113
(% of 9113)
n = 6701
(% of total in row)
Nausea vs. no nausea Nausea vs. no nausea n = 1201 (% of total
nausea in row)
Age, years
≤24 1413 (15.5) 1053 (74.5) 1.1 (1.0-1.2) 1.2 (1.0-1.3) 183 (17.4) 0.9 (0.7-1.2) 0.9 (0.6-1.2)
25-29 3061 (33.6) 2236 (73.0) 1 1 417 (18.6) 1 1
30-34 2939 (32.3) 2191 (74.5) 1.1 (1.0-1.2) 1.0 (0.9-1.2) 399 (18.2) 1.0 (0.8-1.2) 1.0 (0.7-1.3)
≥35 1630 (17.9) 1162 (71.3) 0.9 (0.7-1.2) 0.8 (0.6-1.1) 185 (15.9) 0.8 (0.7-1.0) 0.9 (0.7-1.0)
Marital status
Married/cohabiting 8578 (94.1) 6322 (73.7) 1 1 1137 (18.0) 1 1
Single/divorced/other 535 (5.9) 379 (70.8) 0.9 (0.8-0.9) 0.9 (0.9-1.0) 64 (16.9) 0.9 (0.8-1.1) 0.9 (0.6-1.2)
Parity
0 previous live births 4602 (50.5) 3211 (69.8) 1 1 571 (17.8) 1 1
≥1 previous live births 4511 (49.5) 3490 (77.4) 1.5 (1.4-1.6) 1.5 (1.3-1.7) 630 (18.1) 1.0 (0.7-1.4) 1.0 (0.7-1.4)
Education
Primary school 380 (4.2) 288 (75.8) 1.2 (0.9-1.6) 1.2 (0.8-1.8) 74 (25.7) 1.6 (1.2-2.1) 1.5 (1.1-2.3)
High school 2574 (28.2) 1901 (73.9) 1.0 (0.9-1.3) 1.1 (0.8-1.4) 309 (16.3) 0.9 (0.8-1.0) 0.9 (0.8-1.1)
University or college 5120 (56.2) 3738 (73.0) 1 1 657 (17.6) 1 1
Other education 1039 (11.4) 774 (74.5) 1.1 (1.0-1.2) 1.1 (0.9-1.3) 161 (20.8) 1.2 (1.0-1.6) 1.2 (1.0-1.6)
Working status
Employed, but not as
health care personnel
5417 (59.4) 3874 (71.5) 1 1 629 (16.2) 1 1
Health care personnel 1236 (13.6) 961 (77.8) 1.4 (1.2-1.7) 1.3 (1.1-1.6) 216 (22.5) 1.4 (1.2-1.7) 1.4 (1.2-1.6)
Unemployed 1991 (21.8) 1536 (77.1) 1.3 (1.2-1.5) 1.3 (1.2-1.4) 292 (19.0) 1.2 (1.0-1.3) 1.2 (1.0-1.5)
Other 457 (5.0) 323 (70.7) 1.0 (0.9-1.0) 0.9 (0.9-1.0) 62 (19.2) 1.2 (1.0-1.5) 1.1 (0.9-1.3)
Use of folic acid
Before the pregnancy 311 (3.4) 237 (76.2) 1.0 (0.9-1.2) 1.0 (0.9-1.2) 58 (24.5) 1.5 (1.3-1.9) 1.6 (1.3-1.9)
Before and during pregnancy 4077 (44.7) 3072 (75.3) 1 1 552 (18.0) 1 1
Only during pregnancy 3929 (43.1) 2821 (71.8) 0.8 (0.7-1.0) 0.8 (0.7-1.0) 488 (17.3) 0.9 (0.8-1.1) 0.9 (0.8-1.1)
No 716 (7.9) 517 (72.2) 0.9 (0.7-1.1) 0.8 (0.7-1.1) 93 (18.0) 1.0 (0.6-1.7) 1.0 (0.6-1.7)
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Table 1 Factors related to nausea and treatment of nausea (Continued)
Smoking during pregnancy
No 8227 (90.3) 6125 (74.4) 1 1 1092 (17.8) 1 1
Yes 864 (9.5) 560 (64.8) 0.6 (0.6-0.7) 0.6 (0.5-0.7) 105 (18.8) 1.0 (0.8-1.3) 1.0 (0.8-1.3)
Pregnant population n = 4938
(% of 4938)
n = 3762
(% of total in row)
Adjusted OR
(95 % CI)d
n = 657 (% of total
nausea in row)
Adjusted OR
(95 % CI)d
Multiple pregnancya
No 4817 (97.5) 3667 (76.1) 1 1 636 (17.3) 1 1
Yes 76 (1.5) 65 (85.5) 1.9 (0.8-4.5) 2.0 (0.8-4.9) 17 (26.2) 1.6 (1.1-2.3) 1.6 (1.1-2.4)
Numbers do not add up due to missing numbers
Significant findings are in bold
Abbreviations: OR odds ratio; CI confidence interval
aThis question was only posed to pregnant women (n = 4938). Only pregnant women are included in the analysis
bAdjusted for all other variables in the table with the exception of “multiple pregnancy”
cNausea, no treatment includes women with nausea not using any of the following treatments against nausea: conventional medicines, herbal medicines, homeopathic medicines and dietary supplements
dOnly pregnant women are included in the analysis. Variables included in the model: age, marital status, parity, education, working status, use of folic acid, and smoking
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East Anglia in the UK, The National Bioethics Commit-
tee in Iceland and The Scientific Ethic Board, Provincial
Health Service of Trento in Italy.The STROBE state-
ments were used when writing this paper (Additional
file 1).
Results
During the 2-month study period in each country, a
total of 9113 women were included in the study. Re-
spondents who were residents of Europe (Western, n =
3201; Northern, n= 2820; Eastern, n = 2342) constituted
the largest proportion of the total study population, followed
by North America (n = 533) and Australia (n = 217).
At the time of completing the questionnaire, 4938
(54.2 %) of the women were pregnant and 4175 (45.8 %)
had given birth during the previous year. Among the
pregnant respondents, 1067 (21.6 %), 1656 (33.5 %), and
2214 (44.8 %) were in the first, second, and third trimes-
ter of their pregnancy, respectively, and 182 (3.7 %) were
less than 6 weeks pregnant. A total of 1913 (45.8 %) of
the mothers had an infant less than 24 weeks of age.
Among the respondents, 6701 (73.5 %) had experienced
nausea during pregnancy; 1828 (27.3 %) used some form
of treatment against nausea and 4873 (72.7 %) did not.
Conventional medicines against nausea were used by
1201 (17.9 %) of the women and herbal medicines by
556 (8.3 %).
Both the prevalence of nausea and its treatment varied
by country and region (Table 2 and Fig. 1). The prevalence
of nausea ranged from 62.0 % in Russia to 84.5 % in
Iceland. The proportion of respondents treated among
those who suffered from nausea ranged from 10.4 % in
Finland to 53.2 % in France; the next highest propor-
tions were in Switzerland (48.9 %), Canada (48.0 %),
Table 2 Most common treatments against nausea by region and country
Region or country Nausea Use of any
treatmenta
Use of conventional
medicines
Most frequently used
conventional medicine
Use of herbal
medicines
Most frequently
used herbal medicine
n (%) n (%) n (%) (n) n (%) (n)
Western Europe (n = 3201) 2338 (73.0) 736 (23.0) 449 (14.0) Antihistamines (174) 230 (7.2) Ginger (203)
Austria (n = 82) 54 (65.9) 15 (18.3) 7 (8.5) Antihistamines (3) and
metoclopramide (3)
8 (9.8) Ginger (8)
France (n = 374) 263 (70.3) 140 (37.4) 101 (27.0) Metoclopramide (43) 7 (1.9) Ginger (3)
Italy (n = 926) 645 (69.7) 193 (20.8) 77 (8.3) Metoclopramide (25) 80 (8.6) Ginger (71)
The Netherlands (n = 81) 58 (71.6) 14 (17.3) 12 (14.8) Antihistamines (8) 3 (3.7) Ginger (3)
Switzerland (n = 618) 436 (70.6) 213 (34.5) 165 (26.7) Antihistamines (118) 49 (7.9) Ginger (43)
United Kingdom (n = 1120) 882 (78.8) 161 (14.4) 87 (7.8) Antihistamines (35) 83 (7.4) Ginger (75)
Northern Europe (n = 2820) 2259 (80.1) 533 (18.9) 417 (14.8) Antihistamines (316) 112 (4.0) Ginger (107)
Finland (n = 574) 453 (78.9) 47 (8.2) 37 (6.4) Metoclopramide (17) 3 (0.5) Ginger (3)
Iceland (n = 71) 60 (84.5) 26 (36.6) 17 (23.9) Antihistamines (12) 12 (16.9) Ginger (11)
Norway (n = 1288) 1028 (79.8) 199 (15.5) 120 (9.3) Antihistamines (74) 95 (7.4) Ginger (92)
Sweden (n = 887) 718 (80.9) 261 (29.4) 243 (27.4) Antihistamines (219) 2 (0.2) Ginger (1) and
black pepper (1)
Eastern Europe (n = 2342) 1512 (64.6) 303 (12.9) 146 (6.2) Antacids (56) 121 (5.2) Ginger (69)
Croatia (n = 286) 182 (63.6) 27 (9.4) 14 (4.9) Antacids (5) 1 (0.3) Other herbal
products (1)
Poland (n = 679) 447 (65.8) 81 (11.9) 37 (5.4) Antihistamines (16) 43 (6.3) Ginger (36)
Russia (n = 1008) 625 (62.0) 146 (14.5) 81 (8.0) Antacids (29) 59 (5.9) Artichoke (28)
Serbia (n = 220) 144 (65.5) 29 (13.2) 13 (5.9) Antacids (7) 0 -
Slovenia (n = 149) 114 (76.5) 20 (13.4) 1 (0.7) Antacids (1) 18 (12.1) Ginger (16)
North-America (n = 533) 415 (77.9) 171 (32.1) 137 (25.7) Antihistamines (96) 46 (8.6) Ginger (41)
Canada (n = 236) 177 (75.0) 85 (36.0) 74 (31.4) Antihistamines (68) 19 (8.1) Ginger (18)
USA (n = 297) 238 (80.1) 86 (29.0) 63 (21.2) Ondansetron (29) 27 (9.1) Ginger (23)
Australia (n = 217) 177 (81.6) 85 (39.2) 52 (24.0) Metoclopramide (32) 47 (21.7) Ginger (46)
Total population (n = 9113) 6701 (73.5) 1828 (20.1) 1201 (13.2) Antihistamines (613) 556 (6.1) Ginger (466)
aIncluding conventional medicines, herbal medicines, homeopathic medicines and dietary supplements
Antacids are defined as all medicines with ATC-code A02
Antihistamines are defined as all medicines with ATC-code R06
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and Australia (48.0 %). In 11 countries the treatment
rates were below 30 % (Fig. 1). Among the regions,
Australia (48.0 %) and North America (41.2 %) had the
highest rates of treatment.
The most commonly used conventional medicines
against nausea in the total population were antihistamines,
which were used by 613 respondents (6.7 %) (Table 2 and
Additional file 2). Metoclopramide was the second most
commonly used medicine with 268 respondents (2.9 %).
Antacids (ATC-group A02), ondansetron, and domperi-
done were used by 176 (2.6 %), 54 (0.6 %), and 48 (0.5 %)
respondents, respectively. Conventional medicines were
most commonly used against nausea in Canada, France,
Switzerland and Sweden. The type of conventional
medicine most commonly used among women with nau-
sea differed by region and country, but in the majority of
countries it was either antihistamines or metoclopramide.
An exception was ondansetron, which was the most com-
monly used medicine in the United States, closely
followed by antihistamines. In Croatia, Russia, Serbia, and
Slovenia the most common medicines were antacids, des-
pite heartburn and reflux problems being less prevalent in
these countries (60.5 %, 59.6 %, 52.7 %, and 57.7 %, re-
spectively) compared to the total population (66.0 %). The
countries in Eastern Europe had a low frequency of con-
ventional medicines use. One respondent from Slovenia
reported the use of conventional medicines. Interestingly,
metopimazine was reported to be used against nausea by
Fig. 1 Use of treatment against nausea among women experiencing nausea
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29 respondents, all in France. In Canada, 54 respondents
had used Diclectin®, which is a combination of the antihis-
tamine doxylamine and pyridoxine.
Among the five regions, Australia had the highest fre-
quency of herbal medicine use (21.7 %). Ginger was the
most commonly used herbal medicine in the total popu-
lation (5.1 %) and in most regions and countries. How-
ever, in Russia the most commonly used herbal medicine
was artichoke (2.8 %). In most countries, herbal medicines
were used to a lesser extent than conventional medicines,
with the exception of Slovenia, Poland, Austria, and Italy.
Maternal characteristics as predictors of nausea and
the use of conventional medicines against nausea during
pregnancy are shown in Table 1. Respondents who had
more than one previous live birth, worked as health care
personnel, or were unemployed were more likely to ex-
perience nausea, whereas respondents who used folic
acid during pregnancy only or smoked during pregnancy
were less likely to experience nausea according to ad-
justed models. Respondents who had primary school as
their highest completed education, were health care
personnel, or had used folic acid before the pregnancy
were more likely to have used conventional medicines
against nausea than respondents with characteristics
within the respective reference categories. Multiple
pregnancy was also associated with use of medicines
against nausea.
Women who experienced nausea during pregnancy were
more likely to have any of the acute short-term illnesses
listed in Table 3. These respondents were also more likely
to have four or more co-morbidities in terms of acute
short-term illnesses, any chronic illness, or to have taken
sick leave during pregnancy. This pattern was similar when
comparing respondents who had nausea and used conven-
tional medicines against nausea to the respondents who
experienced nausea without using any treatment. How-
ever, the effect estimates were generally lower than for
nausea alone. Sub analyses including only respondents
pregnant at the time of participation in the study re-
vealed that respondents who experienced nausea were
more likely to have symptoms of depression (EPDS
score ≥13) than respondents without nausea. This was
also true among respondents who had nausea and used
conventional medicines compared to respondents who
experienced nausea without treatment.
In an additional sub analysis we found that time of ges-
tation acted as a plausible effect modifier of the associ-
ation between medicated nausea and comorbidity.
Specifically, respondents early in their pregnancy (≤1 tri-
mester) who treated nausea with conventional medicines
presented a significant 3.1-, 2.8-, and 2.1-fold increased
likelihood of taking sick leave (crude OR: 3.1, 95 % CI:
1.8-5.5), having depressive symptoms during pregnancy
(crude OR: 2.8, 95 % CI: 1.7-4.6), and having heartburn
and reflux problems (crude OR: 2.1, 95 % CI: 1.6-2.6), re-
spectively, compared to respondents with non-medicated
nausea. Such measures of association were of a much
smaller magnitude (30-70 % increased likelihood) in the
stratum comprising only respondents later in their preg-
nancy (>1 trimester). Similar results were observed when
respondents with nausea were compared to those without
nausea (data not shown).
Discussion
Variations were found across countries and regions in the
prevalence of nausea, treatment rates, and types of treat-
ment used against nausea during pregnancy. Cultural differ-
ences reflected in different treatment traditions, differences
between countries with respect to the women’s and general
practitioners’ willingness to treat, and variations in access
to prenatal care and treatments and their relative costs may
explain several of our findings. Among respondents suffer-
ing from nausea, less than one in three used any form of
treatment, and only 18 % had used any medicine against
this complaint. We do not have data on the severity of
nausea, and the respondents may generally suffer from
mild symptoms that are sufficiently managed by non-
pharmacological treatments, such as dietary changes.
However, the low prevalence of treatment may also be ex-
plained by a reluctance of many general practitioners to
treat these women [34], or by an overestimation of the risk
of medicines among pregnant women with nausea [35].
The overall prevalence of nausea (73.5 %) in this study is
in accordance with a recent meta-analysis of NVP includ-
ing 59 studies from various countries [1].
Canada, followed by France, Switzerland and Sweden,
had the highest prevalence of conventional medicines use
against nausea. This finding may be due to the clear and
well known guidelines in this country [36, 37] and the an-
tiemetic Diclectin®, which is approved for use against
NVP. Therefore, simplifying the identification of safe and
effective treatments may possibly increase the use of treat-
ment. Among the European countries, medicine use was
highest in France, which is in line with the results of a
study of drug utilisation in pregnancy that included six
European Registries of Congenital Anomalies in four
European countries: France, Great Britain, Italy, and the
Netherlands [38]. The authors of the study found that the
two centres in France had the highest prevalence of medi-
cine use (80.8 % and 74.2 %), and that antinauseants were
the most frequently consumed drugs in this country (20.9
% and 15.0 %) [38]. We found that several French respon-
dents used metopimazine, a dopamine antagonist, which
was not reported in any of the other countries. This find-
ing is in accordance with a comparative study by Einarson
and colleagues in 1998 in which France was the only
country to list metopimazine as a treatment option [14].
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Table 3 Co-morbidities according to nausea in pregnancy and its treatment
Total population Nausea Crude OR
(95 % CI)
Adjusted OR
(95 % CI)
Nausea, conventional
medicines against nausea
Crude OR (95 % CI) Adjusted OR (95 % CI)
n = 9113
(% of 9113)
n = 6701
(% of 6701)
Nausea vs.
No nausea
Nausea vs.
No nausea
n = 1201 (% of 1201) Nausea, conventional
medicines against nausea
vs. Nausea, no treatmenta
Nausea, conventional
medicines against nausea
vs. Nausea, no treatmenta
Heartburn or reflux problems 6011 (66.0) 4703 (70.2) 2.0 (1.8-2.1) 2.0 (1.8-2.1)e 908 (75.6) 1.4 (1.2-1.7) 1.4 (1.1-1.7)f
Sleeping problems 5207 (57.1) 4107 (61.3) 1.9 (1.7-2.1) 1.9 (1.8-2.1)e 798 (66.4) 1.3 (1.2-1.5) 1.3 (1.2-1.5)f
Constipation 4757 (52.2) 3686 (55.0) 1.5 (1.4-1.7) 1.5 (1.3-1.7)e 678 (56.5) 1.1 (0.9-1.3) 1.1 (0.9-1.3)f
Headache 5014 (55.0) 3983 (59.4) 2.0 (1.9-2.0) 1.9 (1.8-2.0)e 767 (63.9) 1.3 (1.2-1.3) 1.3 (1.2-1.4)f
Pain in neck, back or pelvic girdle 6227 (68.3) 4798 (71.6) 1.7 (1.5-2.0) 1.7 (1.5-1.9)e 910 (75.8) 1.3 (1.1-1.5) 1.3 (1.1-1.6)f
Any chronic illnessb 2273 (24.9) 1738 (25.9) 1.2 (1.2-1.3) 1.2 (1.2-1.3)e 361 (30.1) 1.2 (1.2-1.3) 1.3 (1.0-1.6)f
≥4 co-morbiditiesc 5257 (57.7) 4245 (63.3) 2.4 (2.2-2.6) 2.3 (2.2-2.5)e 849 (70.7) 1.5 (1.3-1.8) 1.5 (1.3-1.8)f
Sick leave during pregnancy 3956 (43.4) 3001 (44.8) 1.2 (1.0-1.5) 1.3 (1.1-1.6)e 625 (52.0) 1.4 (1.1-2.0) 1.5 (1.1-2.2)f
Pregnant population n = 4938
(% of 4938)
n = 3762
(% of 3762)
Crude OR
(95 % CI)
Adjusted OR
(95 % CI)
n = 657
(% of 657)
Crude OR
(95 % CI)
Adjusted OR
(95 % CI)
Symptoms of depression
during pregnancyd
863 (17.5) 718 (19.1) 1.7 (1.6-1-8) 1.5 (1.4-1.6)g 183 (27.9) 1.9 (1.5-2.3) 1.9 (1.5-2.4)h
Abbreviations: OR odds ratio; CI confidence interval
Significant findings are in bold
aNausea, no treatment: Includes women with nausea not using any of the following treatments against nausea: conventional medicines, herbal medicines, homeopathic medicines and dietary supplements.
bAny chronic illness includes asthma, allergy, hypothyroidism, rheumatic disorders, diabetes, epilepsy, depression, anxiety, cardiovascular diseases, and other
c≥ 4 co-morbidities includes women who reported experiencing more than three of the following disorders during pregnancy: heartburn or reflux problems, constipation, common cold, urinary tract infections,
other infections, pain in the neck, back, or pelvic girdle, headache, and sleeping problems.
dOnly women who were pregnant at the time of participating are included (n = 4938). Symptoms of depression were measured by the Edinburgh Postnatal Depression Scale. Symptoms of depression were
defined as an EPDS score of ≥ 13
eAdjusted for age, parity, working status, use of folic acid, and smoking during pregnancy
fAdjusted for age, education, working status, and use of folic acid
gAdjusted for age, parity, working status, smoking during pregnancy, and ≥4 co-morbidities
hAdjusted for education, working status, use of folic acid, multiple pregnancy, and ≥4 co-morbidities
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In Sweden, antihistamines were the most frequently used
medicines against nausea, which is also in line with previ-
ous findings [17].
Antihistamines and metoclopramide were the most
commonly used conventional medicines against nausea
in the vast majority of the countries. The exceptions
were the USA, Croatia, Russia, Serbia, and Slovenia,
where ondansetron (USA) and antacids (Croatia, Russia,
Serbia, and Slovenia) were the most commonly used
medicines against nausea. This is in line with findings of
a study of hyperemesis gravidarum treatments detecting
inter-country variations of frequency of different treat-
ments of which serotonin inhibitors were most fre-
quently used in the USA, antihistamines in Canada,
whereas Australia had the highest reported use of pro-
motility agents such as metoclopramide [39]. Meta-
analyses and epidemiological studies have not found a
higher risk of malformations with antihistamines and
metoclopramide [40–43], and antihistamines are
regarded as a first line treatment according to guide-
lines in both North America and Europe [36, 37, 44–
46]. Recently, the safety of metoclopramide and ondan-
setron has been questioned [47, 48]. In July 2013, the
European Medicines Agency (EMA) recommended
changing the use of metoclopramide to 10 mg three
times a day up to 5 days to reduce the risk of extrapyr-
amidal side effects [48]. As this is seldom long enough
to treat NVP, the change will limit this medicine’s use-
fulness for nausea and vomiting in the pregnant popula-
tion. In 2011, the U.S. Food and Drug Administration
(FDA) raised concerns over cardiovascular safety, suggest-
ing that ondansetron could cause prolonged QT interval,
which can lead to Torsade de Pointes [49]. Electrocardio-
gram (ECG) monitoring in patients with electrolyte abnor-
malities is advised. A recent Danish registry study of
ondansetron use during the first trimester did not detect
any increased risk of malformations [50]. Another unpub-
lished study based on the same registries detected a 2-fold
increase in the prevalence of major congenital heart de-
fects after exposure to ondansetron [51]. Notably, the data
in our study were collected during winter 2011–2012.
Therefore, the medication utilisation pattern may have
changed due to the warnings issued by the EMA (2013)
and FDA (2011) with respect to metoclopramide and
ondansetron, respectively.
Australia had the highest rate of herbal medicine use
against nausea, followed by Iceland and Slovenia. Australia
has previously been reported to have a high prevalence of
herbal medicine and CAM use in pregnancy in general [52,
53], and also more specifically a high use of ginger during
pregnancy [52]. The results with respect to Slovenia were
special; 12.1 % of respondents had used herbal medicine,
but only one respondent had used a conventional medicine
against nausea. This finding may indicate a long tradition
of herbal medicine in Slovenia or a lack of access to con-
ventional medicines.
Ginger was the dominant herbal medicine used against
nausea. Ginger has been reported to be more effective
than placebo and equally effective as vitamin B6 and di-
menhydrinate against nausea in pregnancy [54]. With re-
spect to safety, a cohort study with 1020 ginger-exposed
pregnancies (466 in the first trimester) found no increased
risk of malformations, stillbirth/perinatal death, low birth
weight, preterm birth, or low Apgar score [16]. Russia was
the only country to report the use of artichoke against
nausea. However, no studies of artichoke use in pregnancy
were found, though artichoke has been observed to have
an antiemetic effect in outpatients with dyspeptic syn-
drome [55].
Various maternal characteristics were associated with
nausea and its treatment. Having more than one previ-
ous live birth was associated with nausea, probably be-
cause having additional children results in less time to
rest and relieve the nausea. This finding is in accordance
with previous research [56, 57], but the data are conflict-
ing [4]. Other factors associated with nausea were work-
ing as health care personnel or being unemployed, which
is in line with previous research that found an association
between being a housewife or out of work and nausea
[57, 58]. Respondents who smoked during pregnancy or
who used folic acid during pregnancy were less likely to
report nausea. Decreased risk of nausea among smokers
was observed in several earlier studies [4, 56, 57]. Use of
vitamins in early pregnancy was previously found to be
protective against nausea [57, 59]. Women who take folic
acid before, as well as during, pregnancy are most likely
planning to become pregnant, and this may imply that
they are more attentive to early symptoms of pregnancy
than women who use folic acid only during pregnancy.
Respondents who had a lower education were more
likely to use medicines against nausea. This finding is
in accordance with a Swedish study [17]. Respondents
working as health care professionals were also more
likely to use medicines against nausea, which can be ex-
plained by this group being aware of safe and effective
treatment options for nausea. Multiple pregnancy was
associated with the use of medicines. This may indicate
that use of medicines may act as a marker of severe
forms of nausea, as it is previously found that multiple
pregnancy increase the risk of nausea [56]. In addition,
the severity of NVP symptoms has been associated with
the use of antiemetics [7, 60].
We found a high burden of co-morbidity among re-
spondents experiencing nausea during pregnancy. The
association with symptoms of depression and sick leave in
particular warrants attention. Women who suffer from any
pregnancy-related complaint may tend to seek information
on the internet to a greater extent than women who feel
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well. Therefore, the respondents may be seeking informa-
tion and responding at the peak of their discomfort. How-
ever, symptoms of depression have also been associated
with nausea during pregnancy [7, 9, 60]. Similarly, the asso-
ciation with heartburn and reflux problems is in agreement
with previous studies [61]. Clinicians should be aware of
the high degree of co-morbidity with nausea and routinely
ask women with nausea whether they have reflux problems
or other pregnancy-related ailments.
Our findings indicate that women who have nausea in
early pregnancy, especially those who treat nausea with
medicines, have a high likelihood of experiencing depres-
sive symptoms, heartburn and reflux problems, and taking
sick leave. This is an important clinical finding and em-
phasises how debilitating nausea during pregnancy can be
for these women. General practitioners in contact with
women with NVP should be aware of the high degree of
co-morbidity, examine these women for symptoms of de-
pression and heartburn and reflux problems, and treat
these conditions if present. Special attention should be
paid to women in early pregnancy. Treating heartburn
and reflux problems may alleviate symptoms of NVP and
increase the women’s wellbeing [62]. Major guidelines
suggest antacids as adjunctive therapy against NVP [36,
37, 44].
This study has several strengths and limitations that
should be acknowledged. This is the first multinational
study to simultaneously collect data on the prevalence of
nausea and its treatment, which enables direct compari-
sons between countries and regions. A large number of
women from a variety of countries in different regions of
the world were reached due to the utilisation of a web-
based questionnaire posted on various pregnancy-related
websites. These data provide valuable insights into the
prevalence of nausea and the treatment of this complaint
across countries and regions. Furthermore, the study
population was reasonably comparable to the general
birthing population with respect to age, parity, and smok-
ing habits, though the women in the study population had
a higher education on average [23]. However, the possibil-
ity that the respondents differ from the general birthing
population in ways that our analysis cannot control for
cannot be excluded. In some of the countries (Australia,
Canada, France, Russia, the Netherlands, and the USA),
the study sample was a small proportion of the general
birthing population. For these specific countries, our find-
ings should be generalised with caution.
There are some other limitations that need to be ad-
dressed. First, a conventional response rate could not be
calculated because the questionnaire was only accessible
through websites. However, epidemiological studies have
indicated that web-based recruitment methods have rea-
sonable validity [63, 64]. In addition, women of childbear-
ing age generally have a relatively high internet penetration
rate [65–67]. The fact that we found a prevalence of nausea
very similar to the prevalence reported in the literature,
and that the comparison with the birthing population in
each participating country had high external validity, sup-
ports our approach. However, the higher education of the
respondents may have had an impact on their choice of
treatment. Second, including women at an early stage in
their pregnancy may underestimate the prevalence of nau-
sea, as this complaint often does not occur before gesta-
tional weeks 6–8. However, this only applies to the 182
women (2.0 %) who were less than 6 weeks pregnant at the
time of participation. Thirdly, although we tried to minim-
ise the risk of recall bias by excluding women with a youn-
gest child aged >1 year, this risk cannot be ruled out. In
addition, the EPDS was only measured at one time point
during the pregnancy and two time points are considered
more valid [29]. Finally, we lack information on the severity
of nausea and our results should be interpreted with these
limitations in mind.
Conclusions
The prevalence of nausea was high across all participating
countries, but its treatment varied, possibly due to cultural
differences and differences in attitudes towards medicines.
Women who reported nausea also had a high burden of
co-morbidity, especially heartburn and reflux symptoms.
The association with symptoms of depression and sick
leave warrants attention. These findings will be helpful to
health care personnel involved in the care of pregnant
women with nausea.
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